EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Zanubrutinib monotherapy for IgG4-related head and neck disease

Matthew C Baker, Saurabh Gawde, Audra Horomanski, Robert M Fairchild, Yuhan Liu, Artem Mikelov, Yin Sun, Maria R Vitale, Evan Maestri, Friederike Held, Mariani Deluna, Walter G Park und 12 weitere

Annals of the Rheumatic Diseases · 2026-07

DOI: 10.1016/j.ard.2026.06.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-07. Verfasst von Matthew C Baker und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA. Electronic address: mbake13@stanford.edu. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeiGene.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Immunoglobulin (Ig) G4-related disease (IgG4-RD) is commonly treated with glucocorticoids and B-cell depletion, but cumulative toxicity and relapse underscore the need for alternative approaches. We evaluated the efficacy, safety, and immunological effects of Bruton's tyrosine kinase (BTK) inhibition with zanubrutinib in active IgG4-RD. METHODS: In this phase 2, open-label, proof-of-concept trial, 10 participants with lacrimal and submandibular gland IgG4-RD received zanubrutinib 80 mg twice daily for up to 24 weeks without glucocorticoid induction or background immunosuppression. The primary endpoint was change in lacrimal and submandibular gland volume at week 24 by blinded fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (evaluable n = 8). Secondary endpoints included metabolic imaging parameters, clinical disease activity, serologic biomarkers, and safety. Single-cell RNA sequencing with immune repertoire profiling was performed to define cellular mechanisms. RESULTS: At week 24, mean gland volume decreased by 46.7% (lacrimal) and 29.9% (submandibular) (both P = .008), with concordant reductions in total lesion glycolysis (-91.6 g; P = .05) and total metabolic lesion volume (-20.7 cm³; P = .05). Clinical disease activity improved (IgG4-RD Responder Index -6.0 points; P = .01), alongside reductions in serum IgG4 (-417 mg/dL; P = .008) and circulating plasmablasts. Imaging and serologic changes were strongly correlated. Single-cell analyses demonstrated treatment-associated modulation of B-cell transcriptional programmes, reductions in IgG4-skewed plasmablasts, and attenuation of cytotoxic CD4⁺ T cells. Adverse events were predominantly mild; 1 serious event (COVID-19) occurred off treatment. CONCLUSIONS: Zanubrutinib monotherapy produced substantial imaging-defined and clinical improvements in active glandular IgG4-RD without glucocorticoid induction. BTK inhibition was associated with modulation of B-cell differentiation states and downstream immune programmes, supporting its development as a steroid-sparing, non-B-cell-depleting therapeutic strategy.

Autor:innen und Institutionen

  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA. Electronic address: mbake13@stanford.edu.
  • Institute for Immunity, Transplantation, and Infection, School of Medicine, Stanford University, Stanford, CA, USA.
  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Department of Pathology, Stanford University, Stanford, CA, USA; Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA, USA.
  • Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, USA.

Förderung

  • BeiGene

Zitieren

APA

Baker, M. C., Gawde, S., Horomanski, A., Fairchild, R. M., Liu, Y., Mikelov, A., Sun, Y., Vitale, M. R., Maestri, E., Held, F., Deluna, M., Park, W. G., Siddiqi, H., Taylor, L., Bopardikar, S., Khalighi, M., Franc, B. L., Penta, M., Boyd, S. D., …, & Lanz, T. V. (2026). Zanubrutinib monotherapy for IgG4-related head and neck disease. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.06.020

Vancouver

Baker MC, Gawde S, Horomanski A, Fairchild RM, Liu Y, Mikelov A, et al. Zanubrutinib monotherapy for IgG4-related head and neck disease. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.06.020

BibTeX
@article{Baker2026,
  author = {Baker, Matthew C and Gawde, Saurabh and Horomanski, Audra and Fairchild, Robert M and Liu, Yuhan and Mikelov, Artem and Sun, Yin and Vitale, Maria R and Maestri, Evan and Held, Friederike and Deluna, Mariani and Park, Walter G and Siddiqi, Haziq and Taylor, Lauren and Bopardikar, Sachi and Khalighi, Mehdi and Franc, Benjamin L and Penta, Mrudula and Boyd, Scott D and Khatri, Purvesh and Zhu, Han and Pham, Nancy and Guja, Kip E and Lanz, Tobias V},
  title = {Zanubrutinib monotherapy for IgG4-related head and neck disease},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  doi = {10.1016/j.ard.2026.06.020}
}
Kostenlos starten →